RxDoctor Payments Data

Marissa Knott

Physician Assistant · San Diego, CANPI 1437785870

Payments from drug & device makers

$3,104in general payments, 2019–2025

Across 138 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$721
  • Johnson & Johnson$302
  • Amgen$298
  • Boehringer Ingelheim$244
  • Irhythm Technologies, Inc.$242
  • AstraZeneca$241
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$3,090100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,104 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$29,463
Medicare patients
215
Services billed
444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$173,652
EntrestoSacubitril/Valsartan32$48,038
XareltoRivaroxaban45$47,038
JardianceEmpagliflozin32$38,473
BrilintaTicagrelor19$15,963
Repatha SureclickEvolocumab11$9,403
Metoprolol Succinate112$1,398
Flecainide Acetate14$1,084
ClopidogrelClopidogrel Bisulfate78$1,006
Ezetimibe25$889
Bumetanide18$797
Amiodarone Hcl24$730
Rosuvastatin Calcium76$721
Carvedilol74$678
Atorvastatin Calcium66$625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$173,652124 claims
NovartisEntresto$721$48,03832 claims
Johnson & JohnsonXarelto$302$47,03845 claims
Boehringer IngelheimJardiance$244$38,47332 claims
AstraZenecaBrilinta$241$15,96319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →